Crohn's Disease Clinical Trial
Official title:
A Phase I, Pilot Trial to Evaluate the Safety and Efficacy of Injection of Allogeneic Mesenchymal Bone-Marrow Derived Human Stem Cells in Patients With Fistulizing Crohn's Disease.
To evaluate the role of allogeneic mesenchymal stem cells for treatment of perianal
fistulizing Crohn disease.
Twenty (20) Crohn's disease patients with complex or multiple perianal or rectovaginal
fistulas will be included and will be scheduled to undergo peri-fistula injections after
meeting all inclusion/exclusion criteria's at baseline.
Following the Pilot Phase of four (4) subjects, sixteen (16) subjects are scheduled to
undergo perianal injections and after meeting all inclusion/exclusion criteria's, will be
evaluated at baseline.
Twenty (20) subjects will be treated with 20 million (2 x 10^7) allogeneic MSC's total
divided into 10 injections of 2 million cells/cm of tract in 0.5 ml volume (for total volume
of 5 ml per visit) at 4 week intervals for a maximum of 4 treatment sessions based on the
discretion of the endoscopist at the time of injection..
For patients with more than 6 fistula tracts, the largest of the tracts will be injected.
The first four (4) subjects that receive their initial injections will not be treated less
than 5 days apart. As stated in the above response, these first four (4) patients will have
an initial safety follow up period of one month prior to proceeding with the treatment of
further patients.
Follow up: Clinical (CDAI, PDAI, and perianal examination +/- under anesthesia), and
endoscopic ultrasound will be performed at the time of each treatment. MRI evaluation will be
performed at screening, 4 weeks after the fourth treatment (week 16) and at 16 months, if
fistula closure has not been achieved. Clinical evaluation will be performed at months 1, 3,
6, 12. Endoscopic ultrasound and MRI will also be performed as needed for symptomatic
patients if an abscess is suspected.
Duration of Study participation: 17 Months (Follow-up visits will be at 4, 7, 10 and 16
Months post treatment.
The Allo-hMSCs will be supplied from an allogeneic human mesenchymal stem cell source
manufactured by the University of Miami.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03815851 -
Relationship Between Prophylactic Drainage and Postoperative Complications (PPOI) in Crohn's Patients After Surgery
|
N/A | |
| Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
| Completed |
NCT02883452 -
A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative Colitis
|
Phase 1 | |
| Recruiting |
NCT04777656 -
Use of Crohn's Disease Exclusion Diet on Top of Standard Therapy Versus Standard Therapy Alone in Unstable Pediatric Crohn's Disease Patients.
|
Phase 3 | |
| Terminated |
NCT03017014 -
A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions
|
||
| Recruiting |
NCT06053424 -
Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease
|
Phase 1 | |
| Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
| Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
| Terminated |
NCT02882841 -
MOlecular BIomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection Study In Crohn's Disease Patients
|
N/A | |
| Not yet recruiting |
NCT02858557 -
The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases
|
N/A | |
| Completed |
NCT02542917 -
Home Versus Postal Testing for Faecal Calprotectin: a Feasibility Study
|
||
| Terminated |
NCT02417974 -
Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT)
|
Phase 2 | |
| Completed |
NCT03010787 -
A First Time in Human Study in Healthy Volunteers and Patients
|
Phase 1 | |
| Active, not recruiting |
NCT02316678 -
Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics
|
N/A | |
| Completed |
NCT02154425 -
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
|
Phase 1 | |
| Completed |
NCT02197780 -
Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD
|
N/A | |
| Completed |
NCT02193048 -
Prospective Evaluation of a Scoring System in Patients Newly Diagnosed With Crohn's Disease
|
||
| Completed |
NCT02265588 -
Healthy Approach to Physical and Psychological Problems in Youngsters With IBD (HAPPY-IBD).
|
N/A | |
| Recruiting |
NCT02395354 -
Comparative Prospective Multicenter Randomized Study of Endoscopic Treatment of Stenosis in Crohn´s Disease
|
N/A | |
| Completed |
NCT01958827 -
A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease
|
Phase 3 |